Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare. He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.Analyst’s Disclosure: I/we ha ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 1% on Wednesday.Shares of Absci Corp (NASDAQ:ABSI) fell sharply in pre-market trading after the company reported worse-than-expected quarterly sales results.Absci reported quarterly losses of 20 cents per share which met the analyst consensus estimate. The company reported quarterly sales of $650.000 thousand which missed the analyst consensus estimate of $1.100 million.Absci shares dipped 11% to $2.68 in pre-market trading.Her ...

At 7:22 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening bell.For active traders, premarket trading offers a head start in spotting potential breakouts, reversals, or sharp price swings. These early moves often indicate where momentum may carry into the regular session, making premarket analysis a key part of the trading day.In the Green - Premarket GainersThe following stocks are trading hi ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Absci Corporation (ABSI) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -40.24%. A quarter ago, it was expected that this company would post a loss of $0.19 per share when it actually produced a loss of $0.2, delivering a surprise of -5.26%.Over the last four quarters, the company has surp ...

Absci (NasdaqGS:ABSI) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsAlex Khan - Corporate VP of Finance and Head of Investor RelationsDebanjana Chatterjee - DirectorRansi Somaratne - CMOSean Laaman - Executive DirectorSean McClain - Founder and CEOVamil Divan - Managing DirectorZach Jonasson - CFO and Chief Business OfficerConference Call ParticipantsBrendan Smith - Director and Senior AnalystBrian Cheng - Executive Director and Senior Biotech AnalystCharles Wallace - AnalystGil Blum ...

Absci (NasdaqGS:ABSI) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Company ParticipantsAlex Khan - Corporate VP of Finance and Head of Investor RelationsDebanjana Chatterjee - DirectorRansi Somaratne - CMOSean Laaman - Executive DirectorSean McClain - Founder and CEOVamil Divan - Managing DirectorZach Jonasson - CFO and Chief Business OfficerConference Call ParticipantsBrendan Smith - Director and Senior AnalystBrian Cheng - Executive Director and Senior Biotech AnalystCharles Wallace - AnalystGil Blum ...

Absci (NasdaqGS:ABSI) Q4 2025 Earnings call March 24, 2026 04:30 PM ET Speaker11Good day, and thank you for standing by. Welcome to the Absci Fourth Quarter and Full Year 2025 Business Update Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, we'll open up for questions. To ask a question during the session, you will need to press star one oh one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to __________ Commission file number 001-40646 ABSCI CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of i ...

Exhibit 99.1 Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marke ...